Search alternatives:
significant sup » significant snp (Expand Search), significant gap (Expand Search), significant sex (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search)
sup increase » sd increase (Expand Search), sharp increase (Expand Search), size increase (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
significant sup » significant snp (Expand Search), significant gap (Expand Search), significant sex (Expand Search)
step decrease » sizes decrease (Expand Search), teer decrease (Expand Search)
sup increase » sd increase (Expand Search), sharp increase (Expand Search), size increase (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
-
101
-
102
-
103
-
104
-
105
Effects of time on delivery of SYTOX<sup>TM</sup> on corona treatment at ambient temperature.
Published 2023“…<p>The * indicates statistical significance in the increase of the delivery of SYTOX<sup>TM</sup>. …”
-
106
-
107
Proliferation defects in Opa1 depleted type II NB lineages are suppressed by overexpression of Drp1<sup>SD</sup>.
Published 2022“…Analysis of mitotic type II NBs per brain lobe (C) in mCherry RNAi (10 brain lobes), Drp1<sup>SD</sup> (6), <i>opa1</i> (8), Drp1<sup>SD</sup>;<i>opa1</i> RNAi (10), <i>marf</i> RNAi (12), Drp1<sup>SD</sup>;<i>marf</i> RNAi (10). …”
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
Neulasta<sup>®</sup> and Stimufend<sup>®</sup> formulations.
Published 2024“…There are no clinically significant differences between Stimufend<sup>®</sup> and Neulasta<sup>®</sup>, which was confirmed by the marketing approval for Stimufend<sup>®</sup> by the Food and Drug Administration and the European Medicines Agency.…”
-
120